Dendreon Corp. (Nasdaq: DNDN) narrowed second quarter losses to 79 cents per share from $1.04 per share a year earlier but the biotechnology company withdrew its 2011 revenue outlook due to disappointing sales of its prostate cancer treatment Provenge prompting downgrades. The stock price plunged $23.35 to $12.49.